New Risk • Mar 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩4.3b revenue, or US$2.9m). Announcement • Feb 06
Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026 Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 61, gasan-ro, geumcheon-gu, seoul South Korea New Risk • Aug 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.9b revenue, or US$2.8m). New Risk • Jun 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (₩3.9b revenue, or US$2.9m). Reported Earnings • Mar 25
Full year 2024 earnings released: ₩503 loss per share (vs ₩702 loss in FY 2023) Full year 2024 results: ₩503 loss per share (improved from ₩702 loss in FY 2023). Net loss: ₩8.09b (loss narrowed 19% from FY 2023). New Risk • Feb 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (₩6.0b revenue, or US$4.1m). Announcement • Feb 07
Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2025 Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea Announcement • Jan 25
Curiox Biosystems Launches Curiox C- Free Pluto ALPHA: Affordable, Hassle-Free Cell Washing Automation Curiox Biosystems announced the launch of the Curiox C- Free Pluto ALPHA, the latest addition to the Pluto line of products. This compact and intuitive device redefines cell washing automation, bringing simplicity, reliability, and affordability to labs of all sizes. The Curiox C- Free Pluto AlphaHA replaces traditional centrifuge-based methods, offering a low-main maintenance solution that eliminates bulky hardware. Utilizing a pipette head, it delivers gentle, consistent washing of suspension cells and beads, preserving sample integrity and improving reproducibility. By simplifying workflows and reducing variability, Curiox C- Free PlutoALHA helps researchers achieve more consistent, high-quality results in less time. Key Features: Gentle Washing: Pipette-based technology ensures cell viability by avoiding centrifugation, preserving deliver cells. Effortless Integration: Compact design fits seamlessly into existing workflows, with no need for additional infrastructure. Labware Compatibility: Supports 96-well plates, deep-well plates, and Laminar Wash plates, ensuring immediate adaptability to setup. Minimal Maintenance: Virtually the same as a pipetting station, reducing downtime and operational costs for labs. Affordable Automation: Priced below $30,000, it delivers cutting-edge performance within budget-friendly constraints. Compact Footprint: Its small size ensures efficient use of valuable bench space, making it ideal for labs of all sizes. Workflow Benefits: Pre-configured with Light, Moderate, Heavy, and Ultra wash protocols, the Curiox C- Free Neptune ALPHA minimizes hands-on time for researchers, allowing them to focus on high-value tasks. The elimination of centrifugation, flicking, or resuspension steps streamlines workflows while ensuring reproducibility across experiments. These features are especially valuable for immunophenotyping, cell therapy, and drug discovery applications. Emowering Labs with the Pluto Line: The Pluto product line reflects Curiox's mission to drive innovation and enhance productivity. With a focus on scalability and adaptability, Pluto devices cater to diverse research and clinical needs. Whether for small-scale studies or industrial-scale operations, Curiox C- Free Neptune AlphaHA is a critical step in advancing automated cell washing solutions. Configurations to suit Every Need: Standard Model: Equipped with a fixed 96-channel pipette head and three plate decks, it supports wash cycles from 2 minutes onwards: tailored for precision. Custom Options: Flexible throughput with configurable pipette tips and customizable wash parameters ensures adaptability for specialized workflows. New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Announcement • Jul 27
Curiox Biosystems Co., Ltd announced that it has received KRW 20 billion in funding from KB Securities Co.,Ltd, LS SECURITIES Co., Ltd., JB Woori Capital Co., Ltd, Kiwoom Securities Co., Ltd., KDB Capital Corp., IBK Capital Corporation and other investors On July 26, 2024, Curiox Biosystems Co., Ltd closed the transaction. New Risk • Apr 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (₩6.8b revenue, or US$4.9m). New Risk • Apr 11
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: ₩6.8b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩6.8b revenue, or US$5.0m). 
